Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease.
graft-vs-host disease
hematopoietic
ruxolitinib
stem cell transplantation
steroid refractory
Journal
Journal of experimental pharmacology
ISSN: 1179-1454
Titre abrégé: J Exp Pharmacol
Pays: New Zealand
ID NLM: 101530345
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
09
2020
accepted:
16
11
2020
entrez:
4
12
2020
pubmed:
5
12
2020
medline:
5
12
2020
Statut:
epublish
Résumé
Acute GVHD (aGVHD) is a significant complication after allogeneic hematopoietic cell transplantation (HCT), occurring in up to 70% of HCT recipients. Steroid-refractory aGVHD represents a subset of patients failing initial therapy and is particularly morbid, with only 30% of patients surviving long term. Better therapies are urgently required for these patients. Here, we discuss recent advancements in the management of SR-aGVHD. We review the currently available therapies for SR-aGVHD including the results of the REACH1 and REACH2 trials, which provide the basis for the use of ruxolitinib for the treatment of SR-aGVHD. We additionally discuss newer agents under clinical investigation and will highlight the niche these agents may fill to further improve outcomes in aGVHD patient care.
Identifiants
pubmed: 33273867
doi: 10.2147/JEP.S259290
pii: 259290
pmc: PMC7705269
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
549-557Informations de copyright
© 2020 Abedin and Hamadani.
Déclaration de conflit d'intérêts
Mehdi Hamadani reports consultancy for Incyte during the conduct of the study. The authors report no other potential conflicts of interest for this work.
Références
Bone Marrow Transplant. 2018 Mar;53(3):315-325
pubmed: 29269797
Blood. 2016 Oct 20;128(16):2083-2088
pubmed: 27461930
Bone Marrow Transplant. 2020 Aug;55(8):1580-1587
pubmed: 32203257
Blood. 2018 Mar 22;131(12):1372-1379
pubmed: 29437593
Blood. 2020 May 14;135(20):1739-1749
pubmed: 32160294
Biol Blood Marrow Transplant. 2013 Jul;19(7):1129-33
pubmed: 23623892
Bone Marrow Transplant. 2001 Nov;28(10):945-50
pubmed: 11753549
Bone Marrow Transplant. 2010 May;45(5):919-24
pubmed: 19767783
Biol Blood Marrow Transplant. 2014 May;20(5):640-5
pubmed: 24492144
Sci Transl Med. 2020 Aug 12;12(556):
pubmed: 32801142
Leukemia. 2015 Oct;29(10):2062-8
pubmed: 26228813
N Engl J Med. 2017 Nov 30;377(22):2167-2179
pubmed: 29171820
Transplantation. 2001 Dec 27;72(12):1924-9
pubmed: 11773890
Biol Blood Marrow Transplant. 2016 Jan;22(1):4-10
pubmed: 26386318
Bone Marrow Transplant. 2018 Nov;53(11):1401-1415
pubmed: 29872128
N Engl J Med. 2020 May 7;382(19):1800-1810
pubmed: 32320566
Blood. 2017 Feb 2;129(5):643-649
pubmed: 27899357
Biol Blood Marrow Transplant. 2015 Nov;21(11):1863-1869
pubmed: 26256941
Blood Adv. 2020 Apr 28;4(8):1656-1669
pubmed: 32324888
Biol Blood Marrow Transplant. 2019 Aug;25(8):1689-1694
pubmed: 30965140
Biol Blood Marrow Transplant. 2012 Aug;18(8):1150-63
pubmed: 22510384
Drugs. 2012 Nov 12;72(16):2117-27
pubmed: 23061804
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Blood. 2007 Mar 15;109(6):2657-62
pubmed: 17110457
Leuk Lymphoma. 2019 Sep;60(9):2223-2229
pubmed: 30764681
Biol Blood Marrow Transplant. 2017 Sep;23(9):1478-1484
pubmed: 28495641
Biol Blood Marrow Transplant. 2020 Jul;26(7):1247-1256
pubmed: 32165328
Bone Marrow Transplant. 2010 Aug;45(8):1347-51
pubmed: 19966849
Immunotherapy. 2018 Apr;10(5):391-402
pubmed: 29316837
Blood. 2014 Jun 12;123(24):3832-42
pubmed: 24711661
Biol Blood Marrow Transplant. 2019 Apr;25(4):712-719
pubmed: 30399420
J Clin Oncol. 2005 Apr 20;23(12):2661-8
pubmed: 15837980
Biol Blood Marrow Transplant. 2011 Dec;17(12):1862-8
pubmed: 21745454
Blood. 2020 May 7;135(19):1630-1638
pubmed: 32202630
Lancet Haematol. 2015 Jan;2(1):e21-9
pubmed: 26687425
Biol Blood Marrow Transplant. 2015 Apr;21(4):761-7
pubmed: 25585275
Blood. 2010 Apr 15;115(15):3109-17
pubmed: 20130243
PLoS One. 2014 Oct 07;9(10):e109799
pubmed: 25289677
Biol Blood Marrow Transplant. 2014 Nov;20(11):1677-86
pubmed: 24867779